Adults with chronic kidney disease tied to type 2 diabetes now have strong pooled evidence that finerenone, sold as Kerendia, reduced the combined risk of kidney failure, sustained kidney-function collapse, and kidney death by 23 percent compared with placebo across 13,026 patients followed for a median of roughly three years. The result came from a population that included patients with earlier-stage disease, a group many clinicians had considered unlikely to see meaningful kidney protection from a mineralocorticoid-receptor blocker. The FDA has since approved finerenone to reduce the risk of kidney-function decline, kidney failure, cardiovascular death, non-fatal heart attack, and heart-failure hospitalization in these patients, making the drug one of the few therapies with a dual organ-protection label.
Why finerenone’s 23 percent kidney benefit changes the treatment calculus
For years, the standard playbook for slowing kidney damage in people with type 2 diabetes relied on blood-pressure drugs called ACE inhibitors or angiotensin-receptor blockers, plus newer SGLT2 inhibitors such as empagliflozin. Finerenone works through a different mechanism: it selectively blocks the mineralocorticoid receptor, a pathway that drives inflammation and scarring in both the kidneys and the heart. Older, non-selective drugs in the same class, like spironolactone, carried enough risk of dangerous potassium spikes that doctors avoided them in many kidney patients. That history left a widespread assumption that mineralocorticoid-receptor blockers were too risky, or simply not effective enough, for people whose kidney function had not yet deteriorated severely.
The FIDELITY pooled analysis upended that assumption. By combining two large phase 3 randomized controlled trials, FIDELIO-DKD and FIGARO-DKD, researchers assembled a broad finerenone cohort of 13,026 participants that spanned a wide range of kidney disease severity, from early albumin leakage with preserved filtration rates to advanced disease. The kidney composite endpoint, defined as kidney failure, a sustained drop in estimated glomerular filtration rate of 57 percent or more, or kidney death, occurred 23 percent less often in the finerenone group than in the placebo group, with a hazard ratio of 0.77 and a 95 percent confidence interval of 0.67 to 0.88 (P=0.0002). That statistical strength left little room for the result to be a fluke.
The practical consequence is direct. Patients with type 2 diabetes and chronic kidney disease who are already on standard therapy, including renin-angiotensin-system blockers, now have an additional agent that attacks a distinct biological driver of organ damage. The benefit extended to people with earlier-stage kidney disease, the very group doctors had been most hesitant to treat with this drug class. That shift is reflected in the U.S. label, after regulators reviewed the pivotal data and formally cleared finerenone to lower the risk of serious kidney and heart complications in this high-risk population, as described in the FDA’s approval announcement.
How FIDELIO-DKD and FIGARO-DKD built the case
Each trial tested finerenone against placebo on top of optimized standard care, but with different primary lenses. FIDELIO-DKD focused on kidney outcomes and reported a primary kidney endpoint hazard ratio of 0.82, with a 95 percent confidence interval of 0.73 to 0.93. FIGARO-DKD, published in the New England Journal of Medicine, zeroed in on cardiovascular outcomes. Its primary composite endpoint covered cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for heart failure. That trial deliberately excluded patients with symptomatic heart failure with reduced ejection fraction, meaning its cardiovascular findings applied to a broader, less acutely ill population than typical heart-failure drug trials enroll.
When the two datasets were pooled in the FIDELITY analysis, the combined power allowed researchers to detect benefits that neither trial alone could confirm with the same confidence. The 23 percent reduction in the kidney composite stood out as the headline finding, but investigators also examined all-cause mortality, cardiovascular mortality, and patterns of sudden cardiac death across the pooled cohort. That mortality-focused secondary analysis found signals worth watching, though the composite kidney and cardiovascular endpoints carried the strongest statistical weight.
Importantly, both trials mandated background therapy with a maximally tolerated dose of an ACE inhibitor or angiotensin-receptor blocker. That design choice underscored that finerenone is not a replacement for standard-of-care blockade of the renin–angiotensin system, but a layer added on top. The consistent direction of benefit across prespecified subgroups – including by baseline kidney function and albuminuria – strengthened the argument that the drug’s anti-inflammatory and anti-fibrotic effects are clinically meaningful across the spectrum of diabetic kidney disease.
Where SGLT2 inhibitors fit alongside finerenone
Separately, the SGLT2-inhibitor class has built its own evidence base for kidney and heart protection in type 2 diabetes and chronic kidney disease. Trials such as EMPA-KIDNEY, along with earlier studies in diabetic nephropathy, showed that SGLT2 blockade can slow eGFR decline and cut the risk of progression to kidney failure or cardiovascular death. A meta-analysis of SGLT2 inhibitors documented about a 23 percent reduction in heart-failure hospitalization or cardiovascular death in high-risk patients, a magnitude similar to the kidney composite benefit seen with finerenone in FIDELITY.
The overlap in effect size raises a natural question: do finerenone and SGLT2 inhibitors protect the same pathways, or do they stack? Mechanistically, the drugs act through different targets. SGLT2 inhibitors reduce intraglomerular pressure, promote natriuresis, and shift cardiac metabolism, while finerenone modulates mineralocorticoid-receptor–driven inflammation and fibrosis. That divergence suggests at least partially complementary mechanisms, but clinical proof that combining the two yields additive benefit is still lacking.
Unanswered questions about combination therapy and real-world access
The biggest gap in the evidence is the absence of a head-to-head or factorial trial testing finerenone on top of an SGLT2 inhibitor. Both FIDELIO-DKD and FIGARO-DKD were launched before SGLT2 inhibitors became entrenched as standard kidney-protective therapy, so relatively few participants were taking those agents at baseline. As a result, the pooled FIDELITY dataset cannot definitively answer whether the risk reductions seen with finerenone persist, shrink, or grow when patients are already receiving an SGLT2 inhibitor.
Clinically, that uncertainty leaves physicians balancing potential upside against cost and complexity. In theory, a patient with type 2 diabetes, albuminuric chronic kidney disease, and high cardiovascular risk might benefit from triple therapy: an ACE inhibitor or angiotensin-receptor blocker, an SGLT2 inhibitor, and finerenone. Yet each added drug increases pill burden, monitoring demands, and out-of-pocket expenses. Finerenone also carries a known risk of hyperkalemia, particularly in people with lower baseline kidney function, so clinicians may be cautious about layering it on top of other agents that affect renal hemodynamics.
Access and implementation present further hurdles. Even with regulatory approval in hand, uptake of a new chronic therapy depends on insurance coverage, clinician familiarity, and patient willingness to add another long-term medication. In many health systems, routine potassium and eGFR monitoring is feasible, but in resource-limited settings the need for lab follow-up could restrict safe use. Education around careful dose titration and monitoring may determine how widely the drug is adopted beyond academic centers.
Guideline committees now face the task of integrating finerenone into treatment algorithms that already include ACE inhibitors, angiotensin-receptor blockers, SGLT2 inhibitors, and, for some patients, GLP-1 receptor agonists. One likely near-term approach is to prioritize finerenone for patients with persistent albuminuria despite optimized renin–angiotensin-system blockade and, where available, SGLT2 inhibition, especially if they have additional cardiovascular risk factors. As more post-marketing data accumulate, recommendations may expand or narrow based on real-world safety and effectiveness.
For patients and clinicians, the key message is that the therapeutic landscape for diabetic kidney disease is no longer static. The FIDELITY analysis demonstrates that targeting mineralocorticoid-receptor–mediated inflammation and fibrosis can meaningfully delay serious kidney outcomes, even in earlier disease. While questions remain about ideal combinations, sequencing, and access, finerenone has moved from a theoretical option to a data-backed tool that can be deployed alongside established therapies to better protect both kidneys and heart.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
